IL32 and type 1 diabetes mellitus: Because IL-32 is not expressed in most other mammals and is not targeted by any immunotherapies in clinical development, the field lacks definitive evidence that direct inhibition of IL-32 function would be sufficient to prevent either the initiation of β-cell autoimmunity or the progression of T1D in humans.